查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2018681

非阿片类镇痛贴市场：2026-2032年全球市场预测（按产品类型、技术、药物类型、应用、最终用户和分销管道划分）

Non-opioid Pain Patches Market by Product Type, Technology, Drug Type, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，非鸦片类止痛贴市场价值将达到 8.9706 亿美元，到 2026 年将成长至 10.2429 亿美元，到 2032 年将达到 21.4046 亿美元，年复合成长率为 13.22%。

主要市场统计数据
基准年 2025 8.9706亿美元
预计年份：2026年 1,024,290,000 美元
预测年份 2032 21.4046亿美元
复合年增长率 (%) 13.22%

非オピオイド经皮吸収型镇痛パッチのエコシステムを形作る临床的ニーズ、技术的进歩、および戦略的课题を明らかにする経営层向け概要

非阿片类镇痛贴片市场正日趋成熟，这得益于药物创新、先进材料科学和不断发展的临床实践的融合。随着临床医生和患者寻求局部、不含阿片类药物的替代疗法来应对急性和慢性疼痛途径，新型经皮给药系统正日益受到关注。黏合剂化学、微加工技术和微创给药机制的同步进步，正在提高药物的生物利用度，并提供比传统局部製剂更稳定的治疗效果。

本报告详细概述了技术、临床和给药创新融合如何重塑非鸦片类经皮镇痛策略及其在医疗保健专业人员中的应用。

非阿片类镇痛贴片领域正经历着一场变革，这得益于递送技术、黏合剂科学和实证临床应用等方面的进步。微针阵列（包括可溶性和固体形式）正从学术原型阶段走向大规模生产，使得以往受皮肤渗透性限制的药物分子能够经皮递送。同时，丙烯酸酯、水凝胶和硅胶等黏合剂平台也在不断发展，力求在药物相容性和患者舒适度之间取得平衡，从而有助于提高患者在急性和慢性疾病治疗中的用药依从性。

2025年に施行された米国の関税措置が、经皮疗法のサプライチェーンのレジリエンス、筹资策略、および製造上の意思决定にどのような影响を与えているかに関するエビデンスに基づく分析

美国2025年实施的关税政策，为经皮吸收贴片生产所需的医疗设备供应链带来了明显的摩擦，包括原料采购和零件进口。影响聚合物、黏合剂前驱物、电子感测器模组和专用微针製造设备的关税调整，迫使製造商重新评估与供应商和生产地点的关係。为此，一些公司优先考虑关键材料的近岸采购，选择替代材料来源，并加速垂直整合，以降低成本波动和前置作业时间风险。

黏合剂の化学的特性、投与形态、临床适応症、エンドユーザーチャネル、および薬剤负荷量の选択を、开発および商业化の道筋と结びつける、セグメンテーションに基づく精緻な观点

细分市场洞察阐明了产品开发、监管策略和市场进入计划如何与多样化的患者需求和医疗环境相契合。在考虑黏合剂技术时，黏合剂、水凝胶和硅酮黏合剂在皮肤耐受性、药物相容性和佩戴持续时间方面的差异至关重要，每种黏合剂都需要独特的生物相容性测试和供应链考虑。基于应用的细分市场区分了急性疼痛和慢性疼痛黏合剂。在急性疼痛应用情境中，术后疼痛和运动伤害疼痛尤其重要，因此快速起效和易于移除是优先考虑的因素。另一方面，在慢性疼痛治疗​​中，例如关节炎和神经病变疼痛，持续药物释放、长期耐受性和患者依从性则更为重要。

详细的区域评估说明了关键区域的不同法规结构、支付方趋势和临床基础设施如何影响部署和商业化策略。

区域趋势影响整个非鸦片类贴片市场的投资重点、监管路径和策略伙伴关係。在美洲，完善的临床基础设施和新型镇痛药的高接受率为医院和诊所采用这些药物创造了有利条件；然而，报销谈判和采购流程需要提供量身定制的证据材料，以证明其疗效和实际效用。该地区的供应链考量强调可追溯性和合规性，因此製造商通常会将生产和最终组装地点设置在更靠近终端市场的地方，以控制前置作业时间和关税风险。

对竞争格局进行策略概述，重点在于阐述智慧财产权、伙伴关係、製造能力和证据生成如何决定非鸦片类经皮吸收领域的领导地位。

非鸦片类镇痛贴片市场的竞争格局呈现出两极化的特点：既有成熟的製药和医疗设备公司拓展经皮解决方案，也有专注于微针平台和黏合剂创新技术的专业Start-Ups。主要企业优先考虑整合策略，将专有的给药技术、可靠的临床证据和可扩展的生产能力结合。与微针形状、储液囊密封方法和黏合剂化学成分相关的智慧财产权组合对于保持差异化优势以及在许可和合作谈判中占据主导地位至关重要。

为製造商和相关人员制定可操作的策略挑战，以加快产品分销、加强供应链，并将临床证据与支付方参与和商业化相结合。

产业领导企业应制定一套综合蓝图，在科学差异化和切实可行的上市时间之间取得平衡。优先开发与预期临床应用相符的黏合剂和递送平台。例如，对于需要长期佩戴的慢性疾病，应选择水凝胶或硅基黏合剂；对于短期急性疾病，则应选择丙烯酸酯系统。投资于能够产生疗效比较和患者报告结局 (PRO) 数据的临床项目，并透过与大型外科中心和运动医学诊所的早期合作，建立引人注目的真实世界数据 (REW)。

采用透明、严谨的混合方法研究途径，将临床访谈和供应链访谈与监管、专利和产品文件的技术审查结合。

本执行摘要的研究采用了混合方法，重点在于一手临床数据和严谨的技术审查。一手研究包括对疼痛专家、采购经理、法规事务专家和生产专家进行结构化访谈，以了解实际限制、推广应用驱动因素和采购行为。这些研究结果与对同行评审的临床文献、已发布的监管文件、产品标籤和专利资讯披露的专项审查进行了交叉比对，以确保有关黏合剂化学成分、微针技术和储液器结构的各项技术声明均基于检验的公开文件。

明确结论将非鸦片类经皮疗法的实际实施途径与技术能力、临床证据和操作准备的需求连结起来。

总之，非鸦片类镇痛贴片展现出巨大的治疗和商业性潜力，而这取决于技术创新、临床效用和营运韧性的完美结合。微针技术的进步、多样化的黏合剂化学成分以及储库结构的改进，正在扩展可有效治疗急性和慢性疼痛的经皮方案的范围。成功进入市场需要建立可靠的临床证据、建立能够适应贸易政策和原材料成本波动的灵活且具有韧性的供应链，以及向保险公司和医疗保健系统提供清晰的价值提案。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESGとサステナビリティ分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 非鸦片类镇痛贴市场：依产品类型划分

  • 矩阵补丁
  • 微针贴片
    • 可溶解微针
    • 固体微针
  • 水库补丁
    • 凝胶储液器
    • 液体储层

第九章 非鸦片类镇痛贴片市场：依技术划分

  • 丙烯酸黏合剂
  • ハイドロゲル系黏合剂
  • 硅胶黏合剂

第十章 非鸦片类镇痛贴片市场（依药物类型划分）

  • 辣椒素
  • Lidocaine
  • 非类固醇消炎剂

第十一章 非鸦片类镇痛贴市场：依应用领域划分

  • 急性疼痛
    • 术后疼痛
    • 运动伤害引起的疼痛
  • 慢性疼痛
    • 关节炎
    • 神经性疼痛

第十二章 非鸦片类镇痛贴市场：依最终用户划分

  • 诊所
  • 居家照护
  • 医院
    • 私立医院
    • 公立医院

第十三章 非鸦片类镇痛贴市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房
    • 非处方药
    • 处方笺

第十四章 非鸦片类镇痛贴市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 非鸦片类镇痛贴片市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 非鸦片类镇痛贴市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国非鸦片类止痛贴市场

第十八章：中国非鸦片类镇痛贴市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Astellas Pharma Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Endo International plc
  • Haw Par Corporation Limited
  • Hikma Pharmaceuticals PLC
  • Hisamitsu Pharmaceutical Co., Inc.
  • Hyloris Pharmaceuticals Ltd.
  • IBSA Institut Biochimique SA
  • Johnson & Johnson Services, Inc.
  • Kaleo, Inc.
  • Mallinckrodt Pharmaceuticals plc
  • Medherant Ltd
  • Medtronic plc
  • Mylan NV
  • Novartis AG
  • Perrigo Company plc
  • Purdue Pharma LP
  • Sorrento Therapeutics, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Upsher-Smith Laboratories, Inc.
  • Veridian Healthcare LLC
  • Viatris Inc.
Product Code: MRR-AD36CD897D7B

The Non-opioid Pain Patches Market was valued at USD 897.06 million in 2025 and is projected to grow to USD 1,024.29 million in 2026, with a CAGR of 13.22%, reaching USD 2,140.46 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 897.06 million
Estimated Year [2026] USD 1,024.29 million
Forecast Year [2032] USD 2,140.46 million
CAGR (%) 13.22%

An executive introduction that clarifies clinical needs, technological advancements, and strategic imperatives shaping the non-opioid transdermal pain patch ecosystem

The non-opioid pain patch landscape is maturing at the intersection of pharmaceutical innovation, advanced materials science, and evolving clinical practice. Novel transdermal systems are gaining traction as clinicians and patients seek localized, opioid-sparing alternatives that address both acute and chronic pain pathways. Concurrent advances in adhesive chemistries, microfabrication, and minimally invasive delivery mechanisms are enabling improved drug bioavailability and more consistent therapeutic profiles compared with older topical formats.

Clinicians are increasingly prioritizing products that demonstrate predictable pharmacokinetics, lower systemic exposure, and compatibility with existing care pathways. Meanwhile, manufacturers are aligning product development with patient-centered design considerations such as wearability, skin tolerability, and ease of administration outside clinical settings. As a result, strategic decisions now hinge on integrating clinical evidence, regulatory clarity, and supply chain resilience. The remainder of this executive summary synthesizes these forces, highlighting the pivotal technology shifts, regulatory and trade headwinds, segmentation-driven opportunities, and pragmatic recommendations that industry leaders can deploy to translate technical promise into commercial and clinical impact.

A detailed synthesis of the converging technology, clinical, and delivery innovations that are reshaping non-opioid transdermal analgesic strategies and provider adoption

The landscape for non-opioid pain patches is undergoing transformative shifts driven by converging advances in delivery technologies, adhesive science, and evidence-based clinical adoption. Microneedle arrays, including dissolvable and solid variants, are moving beyond academic prototypes toward scalable manufacturing, enabling transdermal access to molecules previously restricted by skin permeability. At the same time, adhesive platforms such as acrylic, hydrogel, and silicone formulations are evolving to balance drug compatibility with patient comfort, thereby improving adherence in both acute and chronic care settings.

Concurrently, product design is differentiating across matrix, microneedle, and reservoir configurations with attention to reservoir formulations in both gel and liquid forms. These form factors allow more precise dosing control and prolonged release profiles, which in turn reduce the need for systemic analgesics. Clinical pathways are adapting as hospitals, clinics, and home-care providers integrate patches into multimodal pain protocols, emphasizing postoperative and sports-related acute pain as well as chronic indications such as arthritis and neuropathic pain. In addition, digital enablement-ranging from adherence sensors to integration with electronic health records-amplifies the potential to monitor outcomes and support reimbursement conversations. Taken together, these shifts create a more differentiated competitive landscape where clinical validation and manufacturing scale are decisive.

An evidence-based analysis of how 2025 United States tariff measures are affecting supply chain resilience, procurement strategies, and manufacturing decisions for transdermal therapies

United States tariff policy enacted in 2025 has introduced measurable friction across medical device supply chains, raw-material sourcing, and component imports that underpin transdermal patch manufacturing. Tariff adjustments affecting polymers, adhesive precursors, electronic sensor modules, and specialized microneedle production equipment have prompted manufacturers to reassess supplier relationships and production footprints. In response, some firms are prioritizing nearshoring of critical inputs, qualifying alternative material sources, and accelerating vertical integration to buffer cost variability and lead-time risk.

Beyond direct input cost implications, tariffs have influenced commercial decisions such as inventory strategies and contract terms with original equipment manufacturers. Procurement teams are increasingly negotiating long-term supplier agreements to stabilize unit costs and protect production schedules. Regulatory filings and quality control processes have also been affected, as manufacturers revalidate components when suppliers change. Moreover, tariffs have had an indirect effect on innovation timelines by altering capital allocation; companies weighing investments in automation, cleanroom expansion, or microneedle tooling now factor trade policy into capital planning. Ultimately, the tariff environment underscores the importance of supply chain agility, robust supplier qualification programs, and scenario-based cost modeling when bringing new non-opioid patch technologies to market.

A nuanced segmentation-driven perspective that links adhesive chemistry, delivery formats, clinical indications, end-user channels, and drug payload choices to development and commercialization pathways

Segmentation insights reveal how product development, regulatory strategy, and go-to-market planning must align with diverse patient needs and care settings. When considering adhesive technology, distinctions among Acrylic Adhesive, Hydrogel Adhesive, and Silicone Adhesive matter for skin tolerability, drug compatibility, and wear-time performance, each demanding unique biocompatibility testing and supply chain considerations. Application segmentation separates acute and chronic pain pathways; acute use cases emphasize postoperative pain and sports injury pain where rapid onset and ease of removal are priorities, whereas chronic care targets such as arthritis and neuropathic pain focus on sustained delivery, long-term tolerability, and patient adherence.

Product type differentiation between Matrix Patch, Microneedle Patch, and Reservoir Patch drives divergent development priorities. Microneedle options-differentiated into Dissolvable Microneedle and Solid Microneedle approaches-introduce distinct regulatory and manufacturing constraints related to biodegradation and device classification, while Reservoir Patch variants with Gel Reservoir or Liquid Reservoir architectures require rigorous control of drug stability and release kinetics. End-user segmentation across Clinics, Home Care, and Hospitals, with Hospitals further categorized into Private Hospitals and Public Hospitals, informs training, inventory management, and reimbursement pathways. Finally, distribution dynamics across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, with Retail Pharmacy subdivided into Over-The-Counter and Prescription channels, influence labeling, packaging, and patient education strategies. Drug payload considerations among Capsaicin, Lidocaine, and Nonsteroidal Anti-Inflammatory Drug compounds further refine clinical positioning, as each molecule has distinct safety, contraindication, and monitoring profiles that shape labeling and commercialization tactics.

An in-depth regional assessment explaining how differing regulatory frameworks, payer dynamics, and clinical infrastructures in key geographies influence adoption and commercialization strategies

Regional dynamics are shaping investment priorities, regulatory pathways, and strategic partnerships across the non-opioid patch landscape. In the Americas, established clinical infrastructure and high adoption rates of novel analgesic modalities create fertile ground for hospital and clinic uptake, yet reimbursement negotiations and procurement processes require tailored evidence packages that demonstrate comparative effectiveness and real-world utility. Supply chain considerations in this region emphasize traceability and regulatory compliance, with manufacturers often locating production or final assembly closer to end markets to manage lead times and tariff exposure.

Europe, Middle East & Africa presents a heterogeneous regulatory environment where country-specific clinical requirements and reimbursement frameworks necessitate flexible regulatory strategies and localized payer engagement. Collaborative pilot programs with hospital networks can accelerate adoption in centers of excellence, while partnerships with regional distributors help navigate complex import and procurement rules. Asia-Pacific encompasses both advanced markets with sophisticated clinical ecosystems and emerging markets with constrained healthcare budgets. In high-income economies within the region, innovation adoption is driven by clinical leadership and private payers, whereas in emerging markets, manufacturers must optimize cost, supply chain logistics, and simplified training to achieve meaningful penetration. Across all regions, regulatory clarity, clinician education, and demonstrable patient outcomes remain vital to scaling non-opioid patch use.

A strategic profile of the competitive landscape highlighting how IP, partnerships, manufacturing capacity, and evidence generation determine leadership in the non-opioid transdermal sector

Competitive dynamics within the non-opioid pain patch sector are characterized by a mix of established pharmaceutical and device firms expanding into transdermal solutions, alongside specialized startups focusing on microneedle platforms and adhesive innovation. Leading organizations are prioritizing integrated strategies that combine proprietary delivery technologies with robust clinical evidence packages and scalable manufacturing capabilities. Intellectual property portfolios around microneedle geometries, reservoir sealing methods, and adhesive chemistries are central to maintaining differentiation and command licensing or partnership negotiations.

Strategic collaborations between device manufacturers, contract development and manufacturing organizations, and clinical research networks are increasingly common as they accelerate time to clinic while managing capital intensity. In parallel, companies that control key components-such as specialized medical-grade polymers and microfabrication tooling-gain leverage in supplier negotiations and can influence industry standards. New entrants tend to focus on niche clinical indications or unique delivery modalities to establish proof points, whereas incumbent players deploy broader commercialization networks and payer engagement expertise. Across the spectrum, success hinges on harmonizing regulatory strategy, manufacturing scale-up, and post-market surveillance to build clinician confidence and support long-term adoption.

Actionable strategic imperatives for manufacturers and stakeholders to accelerate adoption, strengthen supply chains, and align clinical evidence with payer engagement and commercialization execution

Industry leaders should pursue an integrated roadmap that balances scientific differentiation with pragmatic go-to-market execution. Prioritize development of adhesive and delivery platforms that match the intended clinical use; for example, select hydrogel or silicone adhesives for long-wear chronic indications while favoring acrylic systems for short-duration acute applications. Invest in clinical programs that generate comparative effectiveness and patient-reported outcome data, with early collaborations in high-volume surgical centers and sports medicine clinics to create compelling real-world evidence.

From an operational perspective, diversify supply chains for critical inputs and qualify secondary suppliers to mitigate tariff and geopolitical risks. Explore nearshore manufacturing or regional partnerships to reduce lead times and simplify regulatory filings. Build flexible production lines that can accommodate matrix, reservoir, and microneedle formats to capture multiple therapeutic niches. Engage payers early with health economic models and adherence data to support coverage decisions, and design packaging and labeling strategies that reflect the intended distribution channel-whether hospital pharmacy, online pharmacy, or retail channels requiring OTC or prescription classification. Finally, establish post-market surveillance protocols and digital adherence tools to collect outcomes that reinforce value propositions for clinicians and payers alike.

A transparent and rigorous mixed-methods research approach combining primary clinical and supply chain interviews with technical review of regulatory, patent, and product documentation

The research synthesis underpinning this executive summary used a mixed-methods approach that emphasizes primary clinical input and rigorous technical review. Primary research included structured interviews with pain specialists, procurement leaders, regulatory affairs professionals, and manufacturing experts to capture practical constraints, adoption drivers, and procurement behaviors. These insights were triangulated with a targeted review of peer-reviewed clinical literature, public regulatory filings, product labeling, and patent disclosures to ensure technical assertions about adhesive chemistries, microneedle technologies, and reservoir architectures are grounded in verifiable public materials.

Operational analyses incorporated supplier mapping, component qualification pathways, and manufacturing scale considerations derived from interviews with contract manufacturing organizations and quality leaders. Trade policy impacts were evaluated through analysis of tariff schedules, customs classifications relevant to polymer and device components, and case studies of firms that adjusted sourcing strategies. Throughout the research process, quality control measures such as respondent verification, source triangulation, and methodological transparency were applied to minimize bias and enhance the reliability of conclusions. The resulting insights are intended to inform strategic planning, clinical program design, and commercial execution without relying on proprietary market-sizing assumptions.

A decisive conclusion that ties technological capabilities, clinical evidence needs, and operational readiness to practical adoption pathways for non-opioid transdermal therapies

In summary, non-opioid pain patches represent a compelling therapeutic and commercial opportunity contingent on harmonizing technological innovation with clinical utility and operational resilience. Advances in microneedle technologies, diverse adhesive chemistries, and reservoir architectures are expanding the range of transdermal solutions that can effectively treat both acute and chronic pain indications. Successful market entry depends on generating robust clinical evidence, building flexible and resilient supply chains that can respond to trade-policy and input-cost volatility, and engaging payers and health systems with clear value propositions.

Going forward, stakeholders that align product design with specific clinical pathways, invest in scalable manufacturing and quality systems, and nurture strategic partnerships across distribution channels will be best positioned to translate technical innovation into sustained clinical adoption. The collective movement toward opioid-sparing pain management provides an encouraging clinical backdrop, but converting that potential into routine practice requires disciplined execution across regulatory, commercial, and operational domains. This report's insights aim to guide those decisions with practical, evidence-informed recommendations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Non-opioid Pain Patches Market, by Product Type

  • 8.1. Matrix Patch
  • 8.2. Microneedle Patch
    • 8.2.1. Dissolvable Microneedle
    • 8.2.2. Solid Microneedle
  • 8.3. Reservoir Patch
    • 8.3.1. Gel Reservoir
    • 8.3.2. Liquid Reservoir

9. Non-opioid Pain Patches Market, by Technology

  • 9.1. Acrylic Adhesive
  • 9.2. Hydrogel Adhesive
  • 9.3. Silicone Adhesive

10. Non-opioid Pain Patches Market, by Drug Type

  • 10.1. Capsaicin
  • 10.2. Lidocaine
  • 10.3. Nonsteroidal Anti-Inflammatory Drug

11. Non-opioid Pain Patches Market, by Application

  • 11.1. Acute Pain
    • 11.1.1. Postoperative Pain
    • 11.1.2. Sports Injury Pain
  • 11.2. Chronic Pain
    • 11.2.1. Arthritis
    • 11.2.2. Neuropathic Pain

12. Non-opioid Pain Patches Market, by End User

  • 12.1. Clinics
  • 12.2. Home Care
  • 12.3. Hospitals
    • 12.3.1. Private Hospitals
    • 12.3.2. Public Hospitals

13. Non-opioid Pain Patches Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy
    • 13.3.1. Over-The-Counter
    • 13.3.2. Prescription

14. Non-opioid Pain Patches Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Non-opioid Pain Patches Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Non-opioid Pain Patches Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Non-opioid Pain Patches Market

18. China Non-opioid Pain Patches Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Astellas Pharma Inc.
  • 19.6. Bayer AG
  • 19.7. Boehringer Ingelheim International GmbH
  • 19.8. Endo International plc
  • 19.9. Haw Par Corporation Limited
  • 19.10. Hikma Pharmaceuticals PLC
  • 19.11. Hisamitsu Pharmaceutical Co., Inc.
  • 19.12. Hyloris Pharmaceuticals Ltd.
  • 19.13. IBSA Institut Biochimique SA
  • 19.14. Johnson & Johnson Services, Inc.
  • 19.15. Kaleo, Inc.
  • 19.16. Mallinckrodt Pharmaceuticals plc
  • 19.17. Medherant Ltd
  • 19.18. Medtronic plc
  • 19.19. Mylan N.V.
  • 19.20. Novartis AG
  • 19.21. Perrigo Company plc
  • 19.22. Purdue Pharma L.P.
  • 19.23. Sorrento Therapeutics, Inc.
  • 19.24. Sun Pharmaceutical Industries Ltd.
  • 19.25. Teva Pharmaceutical Industries Ltd.
  • 19.26. Upsher-Smith Laboratories, Inc.
  • 19.27. Veridian Healthcare LLC
  • 19.28. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NON-OPIOID PAIN PATCHES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NON-OPIOID PAIN PATCHES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES NON-OPIOID PAIN PATCHES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA NON-OPIOID PAIN PATCHES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MATRIX PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MATRIX PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MATRIX PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISSOLVABLE MICRONEEDLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISSOLVABLE MICRONEEDLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISSOLVABLE MICRONEEDLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SOLID MICRONEEDLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SOLID MICRONEEDLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SOLID MICRONEEDLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY GEL RESERVOIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY GEL RESERVOIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY GEL RESERVOIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIQUID RESERVOIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIQUID RESERVOIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIQUID RESERVOIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACRYLIC ADHESIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACRYLIC ADHESIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACRYLIC ADHESIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HYDROGEL ADHESIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HYDROGEL ADHESIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HYDROGEL ADHESIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SILICONE ADHESIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SILICONE ADHESIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SILICONE ADHESIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CAPSAICIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CAPSAICIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CAPSAICIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIDOCAINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIDOCAINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIDOCAINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY POSTOPERATIVE PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY POSTOPERATIVE PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY POSTOPERATIVE PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SPORTS INJURY PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SPORTS INJURY PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SPORTS INJURY PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY OVER-THE-COUNTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY OVER-THE-COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 220. GCC NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. GCC NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. GCC NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 223. GCC NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 224. GCC NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. GCC NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. GCC NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. GCC NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 228. GCC NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 229. GCC NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. GCC NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 231. GCC NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. GCC NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 259. G7 NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. G7 NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. G7 NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 262. G7 NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 263. G7 NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. G7 NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. G7 NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 266. G7 NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 267. G7 NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 268. G7 NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. G7 NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 270. G7 NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. G7 NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 272. NATO NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 273. NATO NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. NATO NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 275. NATO NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 276. NATO NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 277. NATO NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. NATO NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. NATO NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 280. NATO NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 281. NATO NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. NATO NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 283. NATO NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 284. NATO NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 285. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES NON-OPIOID PAIN PATCHES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA NON-OPIOID PAIN PATCHES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)